MARK2 and cancer: However, we focused our attention on PACSIN2, DIAPH1, MARK3, ADD3, MAP3K7, and MARK2 cassette exons as these events were validated in both normal and cancer cell lines and in non-pathological and tumor breast specimens (Figure S4).